FM
fazen.markets
healthcare·esfritzh

SELLAS REGAL Trial: GPS Cuts AML Death Risk 41%

0h ago|5 min readStandard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

sellas-life-sciencesgalinpepimut-saml-treatmentregal-trialphase-3-oncology
Sponsoredby Fazen Capital

AiX — Free Expert Advisor

Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.

Myfxbook verified No subscription XAUUSD M15
Get Free EA

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.

Key Takeaways

  • 1SELLAS's Phase 3 REGAL win gives GPS a 41% death-risk reduction and a stated path to a first-half 2027 BLA filing.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

SELLAS Life Sciences Group (NASDAQ: SLS) said on 17 November 2026 that its Phase 3 REGAL trial of galinpepimut-S (GPS) met its primary overall survival endpoint in acute myeloid leukemia, with a hazard ratio of 0.59 and a two-sided p-value of 0.035. Median overall survival reached 24.0 months on GPS versus 14.7 months on best available treatment, a 41% reduction in the risk of death.

Context — why the REGAL readout matters now

The REGAL trial enrolled patients with AML who reached a second or later complete remission after second- or later-line salvage therapy and who could not undergo allogeneic stem cell transplantation. The company describes this population as having very limited options, and the trial was designed to test whether a maintenance vaccine could extend survival where observation or low-intensity drugs are the current standard.

GPS is an investigational WT1-targeting immunotherapeutic cancer vaccine licensed from Memorial Sloan Kettering Cancer Center. It combines four WT1-derived peptides intended to drive both CD4+ and CD8+ T-cell responses across multiple HLA types. The mechanism is maintenance: train the immune system to attack residual WT1-expressing leukemia cells and prolong remission.

What changed is the trigger for disclosure. The topline analysis was run after 80 deaths occurred, matching the pre-specified statistical analysis plan. That event-driven design is what allowed SELLAS to unblind the primary endpoint now rather than at a fixed calendar date.

The company said it plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy and to advance preparations for a Biologics License Application for GPS in the first half of 2027. Secondary endpoints, including leukemia-free survival, measurable residual disease and antigen-specific T-cell dynamics, are still being analyzed and will be presented at a future medical conference and submitted to a peer-reviewed journal.

Data — what the numbers show

The headline comparison is a 9.3-month gap in median overall survival. GPS produced a median of 24.0 months; investigator's choice of best available treatment produced 14.7 months. The hazard ratio of 0.59 means GPS-treated patients had a 41% lower instantaneous risk of death across the follow-up period.

The p-value of 0.035 sits below the conventional 0.05 threshold, and the company said the result is statistically significant and clinically meaningful. The trial randomized 126 patients 1:1 to GPS monotherapy or investigator's choice of best available treatment, which included observation, a hypomethylating agent, and/or venetoclax, and/or low-dose cytarabine.

MeasureGPSBest available treatment
Median overall survival24.0 months14.7 months
Hazard ratio0.59reference
Two-sided p-value0.035—
Patients randomized6363

The 126-patient total and 1:1 ratio are stated in the company's description of the trial, so the per-arm split is implied by the design rather than separately disclosed. On safety, the company said GPS was generally well tolerated, with treatment-related adverse events predominantly grade 1 or 2 and most commonly local injection site reactions. No new safety signals were identified, and the company said both arms were balanced on prognostic stratification factors.

The company also said the number of patients who went on to hematopoietic stem cell transplantation was limited and equally distributed between the study arm and control arm, a point that matters because transplant can independently extend survival.

Analysis — what it means for markets and sectors

SELLAS is a late-stage clinical biopharmaceutical company, so the readout is a binary-style event for its equity story. A registrational Phase 3 win in a high-unmet-need AML maintenance setting gives the company a credible path to a BLA filing in the first half of 2027, contingent on FDA feedback on the accelerated strategy. That sequencing — FDA meeting first, filing second — is the company's stated plan, not an approved timeline.

The readout also carries read-through for the WT1-targeting immunotherapy space and for AML maintenance more broadly. GPS is positioned as an off-the-shelf vaccine, which distinguishes it from autologous cell therapies that require manufacturing lead time. If the label eventually covers second-remission, transplant-ineligible patients, it would sit alongside hypomethylating agents and venetoclax-based regimens that formed the control arm here.

The clearest limitation is that this is topline primary-endpoint data from a single trial. Secondary endpoints, subgroup analyses and the full statistical evaluation are still underway, and the company said those results will come at a medical conference and in a peer-reviewed journal. A 126-patient trial is small, and the p-value of 0.035 is not a wide margin below the significance threshold. The steering committee members who commented on the result include investigators with financial interests related to SELLAS, which the company disclosed.

Positioning around the print is likely to hinge on the FDA interaction. Investors long the name are effectively underwriting an accelerated approval pathway; skeptics will point to the small sample, the reliance on a single primary endpoint and the absence of mature secondary data.

Outlook — what to watch next

The company will host a webcast on 17 November 2026 at 7:45 a.m. Eastern Time to discuss the topline results and next steps, with a replay available on its investor relations site for one year. That call is the first place management may add detail beyond the release.

The next hard catalyst is the FDA meeting on an accelerated filing strategy, followed by the company's stated goal of a BLA submission for GPS in the first half of 2027. Neither the meeting date nor the filing date beyond that half-year window was disclosed.

A third catalyst is the full secondary-endpoint dataset, which the company said will be presented at an upcoming major medical conference and submitted for publication. Leukemia-free survival, measurable residual disease and immune response dynamics are the items to watch, because they determine how durable and how broad the survival benefit looks to regulators and clinicians.

Frequently Asked Questions

What does the REGAL trial result mean for retail investors in SLS?

It means the company's lead asset cleared its registrational primary endpoint, which is the single most important de-risking event a clinical-stage biopharma can report. The stock's reaction will depend on expectations going in, which the report does not quantify. What the report does establish is that SELLAS now intends to pursue an FDA meeting and a BLA filing in the first half of 2027, so the regulatory path — not the trial itself — becomes the next swing factor.

What happens next for SELLAS and galinpepimut-S?

The company said it will meet with the FDA to discuss an accelerated filing strategy and advance BLA preparations for GPS in the first half of 2027. It also said comprehensive statistical evaluation of all secondary endpoints is underway, with detailed results to be presented at an upcoming major medical conference and submitted to a peer-reviewed journal. No dates for the FDA meeting or the conference were disclosed.

Why did the REGAL trial analyze its primary endpoint now?

The topline analysis followed the pre-specified occurrence of 80 deaths, in line with the trial's statistical analysis plan. That is an event-driven design, meaning the readout is triggered by the number of deaths rather than a fixed calendar date. The trial randomized 126 patients 1:1 to GPS or investigator's choice of best available treatment, with overall survival from study entry as the primary endpoint.

Bottom Line

SELLAS's Phase 3 REGAL win gives GPS a 41% death-risk reduction and a stated path to a first-half 2027 BLA filing.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.

Sponsored — AiX

Trade XAUUSD on autopilot — free Expert Advisor

AiX is our free MetaTrader 5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.

Get Free EA

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related